Kohl's Sales Decline Persists, Undermining Turnaround Optimism and Validating DeepValue Caution

What happened

Kohl's stock has sunk following a disappointing earnings report that shows sales keep falling, dashing hopes that a recovery had taken hold after a previous record rally. This setback aligns with the DeepValue master report's assessment that the company's turnaround levers, such as Sephora partnerships and owned brands, remain unproven at scale despite strategic progress. The report highlights persistent negative comparable sales, with Q2 FY2025 comps at -4.2% aided by a one-time settlement, indicating ongoing traffic and demand challenges. Elevated leverage at 5.97x Net Debt/EBITDA and thin interest coverage of 1.85x compound execution risks, exacerbated by recent leadership instability. Overall, the latest data confirms that Kohl's has yet to achieve sustainable comp inflection, casting doubt on near-term recovery prospects.

Implication

The persistent sales slump suggests Kohl's strategic initiatives are insufficient to offset sector headwinds and competitive pressures from off-price retailers, undermining turnaround hopes. High leverage and low interest coverage constrain financial flexibility, increasing vulnerability if comps don't improve promptly. Leadership instability adds execution risk, complicating efforts to realize cost savings and operational efficiencies from initiatives like store closures. Without consecutive quarters of flat or positive comps, as noted in DeepValue's watch items, the thesis for an upgrade remains unproven, and the stock's volatility may persist. Consequently, investors should prioritize monitoring quarterly comps and deleveraging progress, avoiding new positions until these metrics show sustained improvement.

Thesis delta

The latest earnings report reinforces the DeepValue HOLD thesis by confirming that negative comps and high leverage persist, dashing earlier recovery optimism. This validates the report's key risks and watch items, indicating no shift in the cautious stance until management demonstrates concrete progress on comp inflection and balance sheet health. Investors should downgrade any premature bullish expectations and await evidence from upcoming quarters before reconsidering the investment case.